A Phase I/II Study of Vorinostat (SAHA), Cladribine (2-CdA), and Rituximab Shows Significant Activity in Previously Untreated Mantle Cell Lymphoma

被引：0
作者：
Spurgeon, Stephen [1 ]
Chen, Andy I.
Okada, Craig [2 ]
Parekh, Samir [3 ]
Leshchenko, Violetta V. [3 ]
Palmbach, Gundula
Ratterree, Bashi
Subbiah, Nan
Capper, Christine [4 ]
Epner, Elliot M. [5 ]
机构：
[1] Oregon Hlth & Sci Univ, Div Hematol & Med Oncol, Knight Canc Inst, Portland, OR 97201 USA
[2] OHSU Knight Canc Inst, Ctr Hematol Malignancies, Portland, OR USA
[3] Albert Einstein Coll Med, Albert Einstein Canc Ctr, Bronx, NY 10467 USA
[4] Penn State Hershey Canc Inst, Hershey, PA USA
[5] Penn State Univ, Hershey Canc Ctr, Hershey, PA USA
来源：
BLOOD | 2011年 / 118卷 / 21期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：203 / 203
页数：1
相关论文
共 50 条
  • [21] The Final Results of a Phase I Study Using Bortezomib (Velcade), Cladribine, and Rituximab (VCR) in Treating Mantle Cell Lymphoma
    Pu, Jeffrey J.
    Berger, Kristin
    Zheng, Chunlei
    Do, Nhan V.
    Claxton, David F.
    Ehmann, W. Christopher
    Drabick, Joseph J.
    Thomas, Loughran P., Jr.
    Epner, Elliot
    BLOOD, 2023, 142
  • [22] A Phase I/II Study of Lenalidomide in Combination with Rituximab in Relapsed/Refractory Mantle Cell Lymphoma
    Wang, Luhua
    Fayad, Luis
    Hagemeister, Fredrick B.
    Neelapu, Sattva
    Samaniego, Felipe
    McLaughlin, Peter
    Samuels, Barry
    Yi, Qing
    Pro, Barbara
    Fanale, Michelle
    Shah, Jatin
    Younes, Anas
    Bell, Neda
    Knight, Robert
    Zeldis, Jerome B.
    Cabanillas, Fernando
    Kwak, Larry
    Romaguera, Jorge
    BLOOD, 2009, 114 (22) : 1064 - 1065
  • [23] NCCTG phase II trial of 2-chlorodeoxyadenosine (2-CDA) as initial therapy for mantle cell lymphoma: A well-tolerated treatment with promising activity.
    Inwards, D
    Brown, D
    Fonseca, R
    Kurtin, P
    Schroeder, G
    Allmer, C
    Witzig, T
    BLOOD, 1999, 94 (10) : 660A - 660A
  • [24] Phase I Study of Rituximab, Lenalidomide, and Ibrutinib in Previously Untreated Follicular Lymphoma (Alliance 051103)
    Ujjani, Chaitra S.
    Jung, Sin-Ho
    Pitcher, Brandelyn
    Martin, Peter
    Park, Steven I.
    Blum, Kristie A.
    Smith, Sonali M.
    Czuczman, Myron S.
    Davids, Matthew S.
    Leonard, John P.
    Cheson, Bruce D.
    BLOOD, 2015, 126 (23)
  • [25] Mature Results From ECOG Study E1405-A Phase II Study of VcR-CVAD with Maintenance Rituximab for Previously Untreated Mantle Cell Lymphoma
    Kahl, Brad S.
    Li, Hailun
    Smith, Mitchell R.
    Gascoyne, Randy D.
    Yang, David T.
    Paietta, Elisabeth
    Advani, Ranjana H.
    Horning, Sandra J.
    BLOOD, 2012, 120 (21)
  • [26] Toxicity of fludarabine and cyclophosphamide (FC) ± rituximab (R) as initial therapy for patients with previously-untreated mantle cell lymphoma:: results of a randomised phase II study
    Eve, H.
    Smith, P.
    Qian, W.
    Stevens, L.
    Rule, S.
    BRITISH JOURNAL OF HAEMATOLOGY, 2007, 137 : 19 - 19
  • [27] A phase II multicenter trial of hyperCVAD MTX/Ara-C and rituximab in patients with previously untreated mantle cell lymphoma; SWOG 0213
    Bernstein, S. H.
    Epner, E.
    Unger, J. M.
    LeBlanc, M.
    Cebula, E.
    Burack, R.
    Rimsza, L.
    Miller, T. P.
    Fisher, R. I.
    ANNALS OF ONCOLOGY, 2013, 24 (06) : 1587 - 1593
  • [28] Phase II Trial of Ibrutinib in Previously Untreated High-Risk Smoldering Mantle Cell Lymphoma
    Gaulin, Charles
    Jain, Preetesh
    Nair, Ranjit
    Iyer, Swami P.
    Lee, Hun Ju
    Fayad, Luis
    Feng, Lei
    Liu, Yang
    Hill, Holly A.
    Li, Yijing
    Young, Chi
    Kanagal-Shamanna, Rashmi
    Oriabure, Onyeka
    Chen, Wendy
    Siddiqui, Asiya
    Xu, Guofan
    Deswal, Anita
    Iliescu, Cezar
    Badillo, Maria
    Li, Shaoying
    Ky, Michelle
    Avellaneda, Michelle
    Tang, Guilin
    Vega, Francisco
    Flowers, Christopher R.
    Wang, Michael L.
    BLOOD, 2023, 142
  • [29] A phase II study of sequential combination chemotherapy with cyclophosphamide (CTX), prednisone, and 2-chlorodeoxyadenosine (2-CDA) in previously untreated patients with chronic lymphocytic leukemia (CLL).
    Tefferi, A
    Reeder, CB
    Geyer, SM
    Allmer, C
    Li, CY
    Levitt, R
    Michalak, JC
    Addo, F
    Krook, JE
    Witzig, TE
    Schaefer, PL
    Maillard, JA
    BLOOD, 2000, 96 (11) : 296B - 296B
  • [30] Phase II study of cladribine with rituximab (R-2-CdA) therapy in patients with relapsed indolent B-cell non-Hodgkin's lymphoma
    Nagai, H.
    Kusumoto, S.
    Sawada, K.
    Yamaguchi, M.
    Takayama, N.
    Kinoshita, T.
    Motoji, T.
    Omachi, K.
    Ogura, M.
    Hotta, T.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
12345